

Interview Summary	Application No.	Applicant(s)	
	09/639,859	GIRSH, LEONARD S.	
	Examiner	Art Unit	
	Chih-Min Kam	1653	

All participants (applicant, applicant's representative, PTO personnel):

(1) Chih-Min Kam. (3)_____.

(2) Paul Carango. (4)_____.

Date of Interview: 07 April 2005.

Type: a) ☒ Telephonic b) ☐ Video Conference
c) ☐ Personal [copy given to: 1) ☐ applicant 2) ☐ applicant's representative]

Exhibit shown or demonstration conducted: d) ☒ Yes e) ☐ No.

If Yes, brief description: a proposed Examiner's Amendment being faxed to applicant.

Claim(s) discussed: 45, 53, 54, 68, 69, 71, 74, 76 and 104.

Identification of prior art discussed: _____.


Agreement with respect to the claims f) ☒ was reached. g) ☐ was not reached. h) ☐ N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: To cancel claims 53, 54, 68 and 69, and to amend claims 45, 71, 74, 76 and 104 as indicated in the Examiner's Amendment.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.


Examiner's signature, if required

TO: Paul Carango

From : Chih-Min Kam

Patent Examiner

Tel: (571)272-0948

Total Pages: 5

Fax No: (215) 656-2498⁹

**Messages: Proposed Examiner's Amendment or 09/639,859
(Docket No.IPI-04-1174R)**

ABSTRACT

The present invention relates to a therapeutic composition and uses thereof for treatment of damaged tissue, wherein the composition comprises at least one extracellular matrix compound, at least one polar surface active lipid, and a plurality of amino acids having a molar ratio which is characteristic of human breast milk protein; and further comprises a fatty acid, gamma-amino butyric acid or L-carnitine.

Examiner's Amendments to the Claims:

Cancel claims 53, 54, 68 and 69.

Claims 45, 71, 74, 76 and 104 have been amended as follows:

45. (Currently amended) An anabolic medicament for treating a damaged tissue, the medicament comprising:

- a) at least one extracellular matrix compound in an amount effective in the damaged tissue as anti-neo-inflammatory and anti-neo-angiogenetic agent, wherein said extracellular matrix compound is selected from the group consisting of a glycosaminoglycan, a collagen, cartilage, chondroitin sulfate, a glycoprotein, and a proteoglycan;
- b) at least one polar surface active lipid, wherein said polar surface active lipid is selected from the group consisting of a phospholipid, a glycolipid and a lipoprotein; and
- c) a plurality of amino acids having an alpha carbon, the amino acids being present at a molar ratio which is characteristic of human breast milk protein, and wherein no more than 10% of the amino acids are in D-form.

71. (Currently amended) The medicament according to claim 70, wherein said molecular bonding force is selected from the group consisting of van der Waals force and ionic interaction.

Art Unit: 1653

74. (Currently amended) The medicament according to claim 45 further comprising at least one of (a) a mineral; (b) a vitamin; (c) an antioxidant; (d) an omega-3 oil(s); (e) zinc;₂ (f) zinc oxide; (g) Vitamin A; (h) chondroitin sulfate; (i) cartilage; and (j) collagen.

76. (Currently amended) The medicament according to claim 48 further comprising at least one of (a) a mineral; (b) a vitamin; (c) an antioxidant; (d) an omega-3 oil(s); (e) zinc;₂ (f) zinc oxide; (g) Vitamin A; (h) chondroitin sulfate; (i) cartilage; and (j) collagen.

104. (Currently amended) The medicament of claim 45, wherein the damaged tissue is selected from the group consisting of skin, eye, liver, gastro-intestinal organ, kidney, and lung.

Art Unit: 1653

Examiner's Amendments to the specification:

Please replace the original title with the following title:

“Therapeutic Compositions for Treatment of a Damaged Tissue”

Please replace the abstract filed August 16, 2000 with the following abstract on a separate sheet: